Joel Beatty
Stock Analyst at Baird
(4.52)
# 265
Out of 5,105 analysts
201
Total ratings
48.77%
Success rate
31.8%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTNM Contineum Therapeutics | Maintains: Outperform | $16 → $14 | $11.63 | +20.38% | 3 | Nov 24, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $160 → $209 | $167.50 | +24.78% | 5 | Nov 18, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $145 → $125 | $76.36 | +63.70% | 9 | Nov 6, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $10 → $19 | $13.10 | +45.04% | 5 | Oct 16, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $10 → $7 | $4.05 | +72.84% | 3 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $42.13 | +59.03% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $2.53 | +137.15% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $42.11 | -78.63% | 6 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $27.15 | +14.18% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $20.92 | +14.72% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $680 | $877.94 | -22.55% | 7 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $29 | $17.98 | +61.29% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $66 | $75.64 | -12.74% | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $148.17 | +9.33% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $28.50 | +43.86% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $12.55 | +27.49% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $268.80 | -72.84% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $23.62 | +35.48% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $84.19 | -10.92% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $2.58 | +171.32% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $53.31 | +21.93% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $36.23 | +98.73% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.46 | +16,338.36% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.36 | +230.88% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $19.07 | +31.10% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $20.37 | +37.46% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.01 | +696.02% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $2.11 | -40.76% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.23 | +3,477.24% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $70.09 | -17.25% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $34.03 | -29.47% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $7.46 | +141.29% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.39 | +151.05% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $6.69 | +318.54% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $397.55 | -55.98% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $6.23 | +124.72% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $21.53 | +401.63% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $80.82 | -3.49% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $18.39 | +443.77% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $14.36 | +735.65% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.91 | +11,408.95% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.85 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $6.57 | +128.31% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2,400 → $1,200 | $2.46 | +48,680.49% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $10.22 | +85.91% | 3 | Nov 10, 2017 |
Contineum Therapeutics
Nov 24, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $11.63
Upside: +20.38%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160 → $209
Current: $167.50
Upside: +24.78%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145 → $125
Current: $76.36
Upside: +63.70%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10 → $19
Current: $13.10
Upside: +45.04%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $4.05
Upside: +72.84%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $42.13
Upside: +59.03%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $2.53
Upside: +137.15%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $42.11
Upside: -78.63%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $27.15
Upside: +14.18%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $20.92
Upside: +14.72%
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $877.94
Upside: -22.55%
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $17.98
Upside: +61.29%
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $75.64
Upside: -12.74%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $148.17
Upside: +9.33%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $28.50
Upside: +43.86%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $12.55
Upside: +27.49%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $268.80
Upside: -72.84%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $23.62
Upside: +35.48%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $84.19
Upside: -10.92%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $2.58
Upside: +171.32%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $53.31
Upside: +21.93%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $36.23
Upside: +98.73%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.46
Upside: +16,338.36%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.36
Upside: +230.88%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $19.07
Upside: +31.10%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $20.37
Upside: +37.46%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $2.01
Upside: +696.02%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $2.11
Upside: -40.76%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.23
Upside: +3,477.24%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $70.09
Upside: -17.25%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $34.03
Upside: -29.47%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $7.46
Upside: +141.29%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.39
Upside: +151.05%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $6.69
Upside: +318.54%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $397.55
Upside: -55.98%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $6.23
Upside: +124.72%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $21.53
Upside: +401.63%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $80.82
Upside: -3.49%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $18.39
Upside: +443.77%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $14.36
Upside: +735.65%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.91
Upside: +11,408.95%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.85
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $6.57
Upside: +128.31%
Aug 17, 2018
Maintains: Neutral
Price Target: $2,400 → $1,200
Current: $2.46
Upside: +48,680.49%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $10.22
Upside: +85.91%